Cargando…
Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit
BACKGROUND: India witnessed a massive surge of rhino orbital cerebral mucormycosis (ROCM) cases during the second wave of COVID-19, recording the highest number of cases in the world, indeed, an epidemic within the pandemic. OBJECTIVES: To describe the clinical profile of patients with COVID-19-asso...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127177/ http://dx.doi.org/10.1186/s43163-023-00430-2 |
_version_ | 1785030407983464448 |
---|---|
author | Amalanathan, Sophia Satish Kumar, C Abinaya, R Prathiba, K Kumaran Ramesh, Colbert Kavitha, B Malini, A Amudhasubba, Reddy |
author_facet | Amalanathan, Sophia Satish Kumar, C Abinaya, R Prathiba, K Kumaran Ramesh, Colbert Kavitha, B Malini, A Amudhasubba, Reddy |
author_sort | Amalanathan, Sophia |
collection | PubMed |
description | BACKGROUND: India witnessed a massive surge of rhino orbital cerebral mucormycosis (ROCM) cases during the second wave of COVID-19, recording the highest number of cases in the world, indeed, an epidemic within the pandemic. OBJECTIVES: To describe the clinical profile of patients with COVID-19-associated mucormycosis (CAM) and the clinical suspects for mucormycosis. METHODS: This single-center descriptive, observational study/audit was done at Indira Gandhi Medical College, Pondicherry, South India. This study is about the clinical profile of 7 CAM patients and 14 COVID-19 patients who were suspects of CAM, based on their risk factors and clinical symptoms, and were referred to the ENT department. STATISTICAL ANALYSIS: All the descriptive variables were summarized as mean, frequency, and percentages for qualitative data. RESULTS: All 7 CAM patients were COVID-19 positive and were not vaccinated against COVID-19, All 7 were known diabetic, all 7 had steroid therapy for their COVID status, and 5 out of 7 (71%) had uncontrolled diabetes mellitus at the time of diagnosis. Facial pain, nasal discharge, and eye swelling were the presenting symptoms of CAM. Maxillary and ethmoid sinuses were the most commonly involved para nasal sinuses. Four out of seven (57.1%) CAM patients survived after 16 months of follow-up, after surgical and medical treatment for CAM. Of the 14 clinical suspects who were negative for CAM, 2 were negative for COVID-19, their risk factors were brought under control, 3 expired due to COVID complications, and 9 patients are alive till date. CONCLUSION: Uncontrolled diabetes is a risk factor for ROCM/CAM, another possible risk factor is steroid therapy, and we hypothesize that COVID infection could also be a possible risk factor that needs to be studied more extensively in a larger sample. Early clinical suspicion, withdrawal of steroids, rapid control of diabetes mellitus, appropriate investigations, and early surgical intervention combined with medical treatment offers better outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43163-023-00430-2. |
format | Online Article Text |
id | pubmed-10127177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101271772023-04-27 Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit Amalanathan, Sophia Satish Kumar, C Abinaya, R Prathiba, K Kumaran Ramesh, Colbert Kavitha, B Malini, A Amudhasubba, Reddy Egypt J Otolaryngol Original Article BACKGROUND: India witnessed a massive surge of rhino orbital cerebral mucormycosis (ROCM) cases during the second wave of COVID-19, recording the highest number of cases in the world, indeed, an epidemic within the pandemic. OBJECTIVES: To describe the clinical profile of patients with COVID-19-associated mucormycosis (CAM) and the clinical suspects for mucormycosis. METHODS: This single-center descriptive, observational study/audit was done at Indira Gandhi Medical College, Pondicherry, South India. This study is about the clinical profile of 7 CAM patients and 14 COVID-19 patients who were suspects of CAM, based on their risk factors and clinical symptoms, and were referred to the ENT department. STATISTICAL ANALYSIS: All the descriptive variables were summarized as mean, frequency, and percentages for qualitative data. RESULTS: All 7 CAM patients were COVID-19 positive and were not vaccinated against COVID-19, All 7 were known diabetic, all 7 had steroid therapy for their COVID status, and 5 out of 7 (71%) had uncontrolled diabetes mellitus at the time of diagnosis. Facial pain, nasal discharge, and eye swelling were the presenting symptoms of CAM. Maxillary and ethmoid sinuses were the most commonly involved para nasal sinuses. Four out of seven (57.1%) CAM patients survived after 16 months of follow-up, after surgical and medical treatment for CAM. Of the 14 clinical suspects who were negative for CAM, 2 were negative for COVID-19, their risk factors were brought under control, 3 expired due to COVID complications, and 9 patients are alive till date. CONCLUSION: Uncontrolled diabetes is a risk factor for ROCM/CAM, another possible risk factor is steroid therapy, and we hypothesize that COVID infection could also be a possible risk factor that needs to be studied more extensively in a larger sample. Early clinical suspicion, withdrawal of steroids, rapid control of diabetes mellitus, appropriate investigations, and early surgical intervention combined with medical treatment offers better outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43163-023-00430-2. Springer Berlin Heidelberg 2023-04-25 2023 /pmc/articles/PMC10127177/ http://dx.doi.org/10.1186/s43163-023-00430-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Amalanathan, Sophia Satish Kumar, C Abinaya, R Prathiba, K Kumaran Ramesh, Colbert Kavitha, B Malini, A Amudhasubba, Reddy Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title | Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title_full | Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title_fullStr | Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title_full_unstemmed | Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title_short | Clinical profile of COVID-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
title_sort | clinical profile of covid-19-associated mucormycosis patients and the clinical suspects: a descriptive audit |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127177/ http://dx.doi.org/10.1186/s43163-023-00430-2 |
work_keys_str_mv | AT amalanathansophia clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT satishkumarc clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT abinayar clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT prathibak clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT kumaranrameshcolbert clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT kavithab clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT malinia clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit AT amudhasubbareddy clinicalprofileofcovid19associatedmucormycosispatientsandtheclinicalsuspectsadescriptiveaudit |